BALWANT NAGRA: Open Payments
NPI 1639354848 · BUFFALO, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$735 in 39 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $129 · 2025 $735
Food & beverage: $735
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 12 | $183 |
| Janssen Pharmaceuticals, Inc | 10 | $169 |
| Otsuka America Pharmaceutical, Inc. | 4 | $95 |
| Neurocrine BioSciences, Inc. | 3 | $62 |
| Alkermes, Inc. | 3 | $59 |
| Vanda Pharmaceuticals Inc. | 2 | $47 |
| E.R. Squibb & Sons, L.L.C. | 1 | $44 |
| Axsome Therapeutics, Inc. | 2 | $41 |
| Lundbeck LLC | 1 | $18 |
| Luye Pharma (USA) Ltd. | 1 | $18 |
Products named: INVEGA SUSTENNA, UZEDY, ABILIFY ASIMTUFII, INGREZZA, FANAPT, COBENFY, Auvelity, ARISTADA.
Industry payments across NY — which companies pay providers there.
